Drug Trial Radar · NCT07608354
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
326
Planned (sponsor's estimate)
Start
Jun 11, 2026
Primary completion
Feb 6, 2029
Study completion Feb 6, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Conditions
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Interventions
EplontersenDrug
Eplontersen delivered subcutaneously, once every 4 weeks
ALXN2220Biological
ALXN2220 delivered intravenously, once every 4 weeks
PlaceboOther
Placebo delivered intravenously, once every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cardiopulmonary exercise test peak VO2Time frame: 52 week
Locations
76 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California
Research Site
San Francisco, California
Research Site
Stanford, California
Research Site
Aurora, Colorado
Research Site
Washington D.C., District of Columbia
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Weston, Florida
Research Site
Chicago, Illinois
Research Site
Boston, Massachusetts
Research Site
Kansas City, Missouri
Research Site
St Louis, Missouri
Research Site
New York, New York
Research Site
Chapel Hill, North Carolina
Research Site
Durham, North Carolina
Research Site
Cleveland, Ohio
Research Site
Portland, Oregon
Research Site
Danville, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Germantown, Tennessee
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Salt Lake City, Utah
Research Site
Falls Church, Virginia
Research Site
Calgary, Alberta, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
London, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Changsha, China
Research Site
Chongqing, China
Research Site
Guangzhou, China
Research Site
Hangzhou, China
Research Site
Créteil, France
Research Site
Marseille, France
Research Site
Rennes, France
Research Site
Toulouse, France
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.